Title: Longitudinal symptom transitions predict incident tuberculosis risk among persons

deprived of liberty in Brazil

Authors: Jung, Esther* (1), Bampi, José Victor Bortolotto (2), da Silva, Alessandra

Moura (2), Liu, Yiran E. (1,3,4), Tsuha, Daniel Henrique (2), Salindri, Argita D. (1),

Santos, Andrea da Silva (5), de Oliveira, Roberto Dias (5,6), Croda, Julio (2,7,8),

Andrews, Jason R. (1)

*Corresponding Author: Esther Jung

Stanford University School of Medicine, 240 Pasteur Dr, Stanford, CA 94304-1049

esthjung@stanford.edu, (858)260-8377

Affiliations:

1. Stanford University School of Medicine, Stanford, California

2. Federal University of Mato Grosso do Sul, Campo Grande, Brazil

3. Yale University School of Medicine, New Haven, Connecticut

4. Yale Law School, New Haven, Connecticut

5. Federal University of Grande Dourados, Dourados, Brazil

6. State University of Mato Grosso do Sul, Dourados, Brazil

7. Oswaldo Cruz Foundation, Campo Grande, Brazil

8. Yale University School of Public Health, New Haven, Connecticut

Keywords: tuberculosis; asymptomatic; prisons; active case finding; screening

ABSTRACT (100 words)

Tuberculosis (TB) screening often relies on cross-sectional symptom assessment. To

determine the added value of longitudinal symptom monitoring, we conducted a

prospective cohort study among 2,282 incarcerated men in Brazil without TB. Every four

months, participants were assessed for symptoms and incident TB (Xpert or culture

positive). At baseline, 23% of participants reported symptoms. Among those

asymptomatic at baseline, 43% developed symptoms within two years. Compared to

remaining asymptomatic, developing symptoms was associated with higher TB risk,

while remaining symptomatic was not associated. Longitudinal symptom monitoring

may provide value beyond cross-sectional symptom assessment and enhance TB

screening in high-risk settings.

BACKGROUND

Tuberculosis (TB) continues to pose a major global health challenge[1]. Early detection and treatment are essential to interrupt transmission and improve outcomes, particularly in high-risk populations. Efforts to identify individuals living with TB often leverage symptom screening to prioritize individuals for confirmatory molecular rapid diagnostic tests[2]. However, conventional approaches to TB screening typically only assess symptoms present at the time of screening entry, which may not capture the dynamic nature of symptom changes during TB disease progression[3,4].

Symptoms that are typically classified as features of TB[5], such as cough, fever, night sweats, and weight loss, can fluctuate over the course of disease[6]. In high-risk populations such as persons deprived of liberty (PDL), these symptoms may also be caused by other common conditions, including upper respiratory tract infections, pneumonia, chronic obstructive lung disease and tobacco smoking[7]. Moreover, recent studies reveal that over 50% of individuals living with undiagnosed TB do not report symptoms at the time of diagnosis[1,8]. Together, the non-specific presentation of TB and high prevalence of asymptomatic TB may limit the ability of cross-sectional symptom screening to reliably identify individuals at imminent risk of active TB, resulting in continued transmission[8,9].

Longitudinal monitoring of symptoms offers an opportunity to overcome some of these challenges by capturing individuals' changes in symptom status over time, including new onset, persistence, or resolution. This may provide additional predictive value for

disease, improve identification of individuals at high risk of TB, or indicate higher risk for

future evaluations, thereby facilitating the prioritization of confirmatory diagnostic

testing.

Prisons harbor some of the highest TB incidence and transmission rates worldwide[10–12],

and the World Health Organization recommends systematic screening be performed

among incarcerated populations at least yearly[2]. However, active case finding is not

widely implemented in most prisons in high-burden countries, partly due to resource

constraints. Understanding how TB symptoms evolve in such settings could inform

more resource-efficient screening approaches, yet longitudinal symptom trajectories in

high-risk populations remain uncharacterized.

To address this knowledge gap, we characterized longitudinal symptom trajectories in a

cohort of incarcerated individuals who were evaluated for TB symptoms and tested for

TB every four months. We assessed the relationship between symptom transitions and

risk of incident TB.

METHODS

We performed systematic screening for TB every four months from February 2023 to

September 2025 in two all-male prisons in the Brazilian state of Mato Grosso do Sul.

After providing informed consent to participate, participants completed a standardized

symptom questionnaire, administered by study nurses, to ascertain the presence of

cough, fever, night sweats, weight loss, chest pain, or dyspnea. Presence of each

symptom at each visit was assessed through yes/no questions (i.e. "Do you have a

cough?"). An individual was considered symptomatic if they confirmed the presence of

any of these symptoms.

At baseline, all consenting participants, regardless of symptoms, had a posterior-

anterior chest radiograph performed and two sputum samples collected for testing by

culture and Xpert® MTB/RIF Ultra (hereinafter "Xpert"). Chest radiographs were

evaluated using automated detection software LunitTB (South Korea; version v3.1.5.1),

which outputs a numerical TB risk score on a continuous scale between 0 and 100.

At each four-month follow-up visit, procedures were repeated: symptom assessment, a

single sputum sample collection, and chest radiography. Symptom status transitions

over sequential four-month intervals were categorized as asymptomatic-to-symptomatic,

symptomatic-to-asymptomatic, persistently symptomatic, or persistently asymptomatic.

Incident TB was defined by at least one positive sputum culture or Xpert result.

Eligibility was restricted to those with negative baseline Xpert and culture results at

baseline to ensure participants did not have prevalent TB. Only participants who

completed at least one follow-up visit during the study period were included, to permit

longitudinal assessment of symptom status and incident TB.

Given the frequent transfers and movement within the prison system, nearly 25% of

individuals enrolled in the cohort missed follow-up visits intermittently. We excluded

individuals with non-consecutive symptom information, as gaps in reporting precluded

reliable classification of symptom transitions across sequential four-month intervals into

the predefined symptom trajectory categories.

We used the chi-square and Kruskal-Wallis tests to compare baseline demographic and

clinical characteristics across symptom transition groups in the first four-month interval.

In supplementary analyses, we evaluated all four-month symptom transitions across the

study period to identify predictors associated with developing or resolving symptoms.

We performed modified Poisson regression with robust standard errors clustered at the

individual level to estimate adjusted risk ratios (aRRs)[13]. Models adjusted for the

following covariates: age, prison, prior TB, exposure to symptomatic cellmates (yes/no),

TB contact (ever/never), current smoking status, any drug use, duration of incarceration,

and binary LunitTB x-ray score using a threshold of 50 as a proxy for baseline lung

abnormalities. Separate models were constructed for individuals who were

asymptomatic at the prior visit (assessing the risk of becoming symptomatic) and for

those who were symptomatic at the prior visit (assessing the risk of becoming

asymptomatic).

Specific symptom-level transition patterns were summarized descriptively by calculating

the proportion of each individual TB-related symptom reported at visits where a

transition occurred, distinguishing between new onset, resolution, and persistent

symptoms.

We also characterized how long participants remained in their initial symptom state

during follow-up using survival analysis. For symptomatic individuals, the event was the

first resolution of symptoms, while for asymptomatic individuals, the event was the first

acquisition of symptoms. Participants were censored at TB diagnosis, loss to follow-up,

or last study visit.

For the primary analysis, we assessed whether symptom transitions during the

preceding four-month interval were associated with incident TB diagnosed at the

subsequent visit, using the same modified Poisson framework described above.

Persistently asymptomatic individuals served as the reference category. All analyses

were conducted in R (version 4.4.1).

Ethical approval was obtained from the Research Ethics Committee of the Federal

University of Mato Grosso do Sul, the Brazilian National Commission for Ethics in

Research, and the Stanford University Research Ethics Committee.

RESULTS

After applying inclusion criteria, our study identified 2,282 participants without TB at

baseline who were assessed for symptoms at two or more consecutive visits between

February 2023 and September 2025. The median baseline age of participants was 33

years (IQR 28-40), over 80% of participants were Black or mixed race (1,854/2,282),

and most participants did not complete high school (83%) (Table 1).

The majority of individuals reported no TB symptoms at baseline (1,747/2,282, 76.5%)

and 62.1% (1,417/2,282) remained asymptomatic at the first follow-up. Notably, 57%

(35/61) of incident TB cases occurred among participants who remained asymptomatic.

Among those asymptomatic at baseline, 14.5% developed symptoms by the first follow-

up. Of the 23.4% symptomatic at baseline, 40% remained symptomatic and 60%

reported resolution (Table 1). Several characteristics differed significantly across

transition groups, with individuals with persistent symptoms showing the highest

prevalence of these factors: previous TB (25.1%), exposure to symptomatic cellmates

(61.4%), current smoking (76.7%), and any drug use (69.8%) (Table 1).

Among participants symptomatic at baseline (n = 535), the probability of remaining

symptomatic declined steeply to 40.2% at the first follow-up, 19.3% at the second, and

7.6% by the last visit. In contrast, symptom absence was more stable: among those

asymptomatic at baseline (n = 1,749), 81.1% remained asymptomatic at the first follow-

up and 43.8% were still asymptomatic at the last visit (Supplementary Figure 1).

Symptom-level transitions revealed that cough (with or without sputum production) was

the most frequently reported symptom among those developing symptoms (66%) and

among those resolving symptoms (68%). Other common symptoms associated with

symptom changes included chest pain, breathing difficulty, weight loss, and fever

(Supplementary Figure 2).

When evaluating predictors for symptom transitions longitudinally among previously

asymptomatic individuals, the onset of any TB symptom within the subsequent four-

month interval was associated with a previous TB diagnosis (aRR 1.26; 95% CI 1.08-

1.47; p = 0.004), current smoking (aRR 1.81; 95% CI 1.53-2.15; p < 0.001), past

smoking (aRR 1.34; 95% CI 1.09-1.66; p = 0.005), any drug use (aRR 1.23; 95% CI

1.08-1.41; p = 0.002), and exposure to symptomatic cellmates (aRR 1.30; 95% CI 1.15-

1.47; p < 0.001). Among previously symptomatic individuals, resolution of symptoms

was less likely among those who reported current smoking (aRR 0.82; 95% CI 0.72-

0.92; p = 0.001) or any drug use (aRR 0.88; 95% CI 0.79-0.97; p = 0.010)

(Supplementary Table 1). In interaction models, these predictors did not significantly

modify the association between symptom transitions and TB risk.

Longitudinal analyses showed that compared to persistently asymptomatic individuals,

transitioning from an asymptomatic to a symptomatic state within a four-month interval

was significantly associated with incident TB (aRR 2.11; 95% CI 1.45-3.07). In contrast,

remaining symptomatic (aRR 1.05; 95% CI 0.60-1.85) or resolution from symptomatic to

asymptomatic (aRR 1.02; 95% CI 0.61-1.68) were not significantly associated with TB

risk, compared to those who stayed persistently asymptomatic (Figure 1).

DISCUSSION

In our longitudinal cohort study in two high-incidence prisons, we found that TB-related

symptoms followed dynamic trajectories over four-month intervals. Between enrollment

and the first follow-up visit just four months later, nearly one in seven (14.5%)

developed new symptoms, and 60% of those symptomatic at baseline reported

resolution, underscoring the fluctuating nature of TB-related symptom reporting in this

population. These observations align with a recent systematic review describing the

natural history of pulmonary TB as heterogeneous trajectories with frequent movement

between symptom states, rather than a linear progression to disease[14].

Importantly, more than half of all incident TB cases (57%, 35/61) occurred among

participants who remained asymptomatic at both visits, highlighting the substantial

limitations of symptom-based screening in this setting. Prior studies in prisons and other

high-risk congregate settings have similarly documented that reliance on symptom-

based screening alone misses a considerable fraction of active TB cases, supporting

the need for repeated active case-finding[4,15]. Together, these findings underscore that

cross-sectional symptom screening alone fails to capture a large proportion of active

TB. Although our study was not designed to assess the additional yield of repeated

symptom assessments, longitudinal monitoring may provide value in understanding

disease progression, particularly when combined with complementary strategies such

as routine sputum testing or radiographic evaluation.

Specifically, our analyses demonstrate that participants who developed new symptoms

had more than double the risk of TB diagnosis compared to those who remained

asymptomatic, while persistent symptoms conferred no excess risk. This pattern

suggests that symptom emergence, rather than chronic symptom presence, offers

greater resolution for identifying short-term risk. This may reflect the high sensitivity of

our combined diagnostic strategy, which likely detected new TB cases rapidly, leaving

few recent-onset cases undiagnosed. In contrast, participants with persistent symptoms

may have alternative or unresolved etiologies, such as concomitant respiratory

infections, which could obscure the relationship with incident TB.

We also identified key factors associated with four-month symptom transitions. Among

previously asymptomatic individuals, previous TB, current and past smoking, and

exposure to symptomatic cellmates increased the risk of developing symptoms. In

contrast, current smoking and drug use were associated with persistent symptoms.

While these predictors shaped symptom trajectories, they did not significantly modify

the primary association between transitions and TB risk in interaction models.

Nonetheless, combining repeated symptom assessments with knowledge of exposure-

related risk factors may allow public health programs to more precisely target diagnostic

interventions toward those at highest short-term TB risk.

Our study had several limitations. Symptom reporting relied entirely on self-report,

which may be influenced by recall bias. Additionally, the four-month interval between

screenings may not have captured shorter-term or transient symptom fluctuations.

Excluding participants with intermittently missing visits may have introduced bias by

removing those with less stable follow-up due to transfer or refusal. Despite these

limitations, our findings offer important insights into the temporal dynamics of TB

symptoms and their potential utility in prioritizing individuals at highest risk for diagnostic

screening and treatment.

In conclusion, longitudinal assessment of TB-related symptoms reveals dynamic

patterns of emergence and resolution that identify individuals at elevated short-term risk

of active disease. Our findings suggest that symptom trajectory monitoring can

complement existing tools to strengthen case detection. Algorithms prioritizing

individuals with either new-onset symptoms or radiographic abnormalities for molecular

testing may improve sensitivity and cost-effectiveness in high-transmission, resource-

limited settings. Future studies should assess how integrating longitudinal symptom

monitoring, radiography, and rapid diagnostics can be operationalized to optimize

detection and reduce transmission.

Acknowledgements EJ, JRA, and JC conceived of the study. JRA, JC, and RDO

developed the study plans. AmdS and AdSS enrolled participants and collected data.

DHT performed data management. EJ, JVBB, YL, ADS, and JRA designed and

performed the data analysis. EJ and JVBB wrote the manuscript. All authors contributed

to revising the manuscript.

The authors acknowledge the use of ChatGPT (GPT-4, OpenAI) for troubleshooting

coding errors and minor grammar checking. AI was not used for generation of

conclusions or interpretation of results. All content and analyses were independently

verified by the authors, who take full responsibility for the manuscript.

Funding This work was supported by Brazil's Ministry of Health; Brazil's National

Council for Scientific and Technological Development [CNPq; 404182/2019-4 to JC] and

the U.S. National Institutes of Health [R01AI130058, K24AI182647 to JRA].

Conflicts of interest The authors do not declare any conflicts of interests in preparing

this article.

Data availability Analytic code is available at https://github.com/Andrews-Lab-

Stanford/LongitudinalTBSymptoms_BrazilPrisons.git

274 **Table 1.** Characteristics of participants by symptom transition between baseline and

275 first follow-up visit (N = 2,282)

Characteristics	Overall (N = 2,282)	First 4-month interval symptom transition				p-value*
		Persistently asymptomatic (n = 1,417)	Persistently symptomatic (n = 215)	Asymptomatic to Symptomatic (n = 330)	Symptomatic to Asymptomatic (n = 320)	
Median age (IQR)	33 (28, 40)	33 (28, 40)	33 (28, 40)	32 (27, 39)	33 (27, 40)	0.208
Incident TB	61 (2.7)	35 (2.5)	17 (5.2)	5 (1.6)	4 (1.9)	0.018
Ethnicity						0.204
White	419 (18.4)	251 (17.7)	40 (18.6)	57 (17.3)	71 (22.2)	
Black	217 (9.5)	127 (8.9)	27 (12.6)	33 (10.0)	30 (9.4)	
Mixed	1,637 (71.7)	1,034 (73.0)	145 (67.4)	239 (72.4)	219 (68.4)	
Asian	8 (0.4)	4 (0.3)	3 (1.4)	1 (0.3)	0 (0)	
Indigenous	1 (<0.1)	1 (<0.1)	0 (0)	0 (0)	0 (0)	
Education						0.562
Less than high school	1,893 (83.0)	1,175 (82.9)	181 (84.2)	279 (84.5)	258 (80.6)	
Completed high school	389 (17.0)	242 (17.1)	34 (15.8)	51 (15.5)	62 (19.4)	
Prison						0.256
EPJFC	1,745 (76.5)	1,089 (76.9)	165 (76.7)	239 (72.4)	252 (78.8)	
IPCG	537 (23.5)	328 (23.1)	50 (23.3)	91 (27.8)	68 (21.3)	
Previous TB	409 (17.9)	225 (15.9)	54 (25.1)	67 (20.3)	63 (19.7)	0.004
TB contact	1,335 (58.5)	818 (57.7)	135 (62.8)	204 (61.8)	178 (55.6)	0.239
Symptomatic cellmates	854 (37.4)	415 (29.3)	132 (61.4)	126 (38.2)	181 (56.6)	<0.001
Current smoking	1,342 (58.8)	741 (52.3)	165 (76.7)	220 (66.7)	216 (67.5)	<0.001
Any drug use	1,416 (62.1)	829 (58.5)	150 (69.8)	226 (68.5)	211 (65.9)	<0.001
LunitTB Score at Baseline						0.961
<50	1,584 (69.4)	984 (69.4)	146 (67.9)	230 (69.7)	224 (70.0)	
≥50	698 (30.6)	433 (30.6)	69 (32.1)	100 (30.3)	96 (30.0)	
Months incarcerated, median (IQR)	12 (2, 44)	13 (2, 41)	14 (2, 71)	11 (2, 34)	9 (1, 61)	0.213

276 No (% of column n) unless otherwise specified.

277 *Pearson's Chi-squared test; Kruskal-Wallis test

279   **Figure 1**. Adjusted risk of incident TB by symptom transitions over four-month intervals

Symptom transition	N	TB (%)	aRR (95% CI)
Asymptomatic → Asymptomatic	5060	81 (1.6)	Reference
Asymptomatic → Symptomatic	1092	41 (3.8)	2.11 (1.45-3.07)
Symptomatic → Symptomatic	755	15 (2.0)	1.05 (0.60-1.86)
Symptomatic → Asymptomatic	1025	18 (1.8)	1.02 (0.61-1.68)

Adjusted Risk Ratio (95% CI)

Adjusted risk ratios (aRRs) represent adjusted risk of TB diagnosed by sputum culture or Xpert within the same four-month interval as the symptom

transition. Models adjust for baseline characteristics including age, prison, prior TB, smoking, drug use, duration of incarceration, symptomatic cellmates,

TB contact, and Lunit x-ray score.

Alt text: Forest plot showing adjusted risk of incident tuberculosis by symptom transitions over four-month intervals. Compared with participants who

remained asymptomatic, those who became symptomatic had over twice the risk of TB. Risks for persistent or resolving symptoms were similar to the

reference group.

REFERENCES

1. World Health Organization. Global Tuberculosis Report 2024. https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/tb-reports/global-tuberculosis-report-2024 (2024).

2. World Health Organization. *WHO Consolidated Guidelines on Tuberculosis. Module 2: Screening - Systematic Screening for Tuberculosis Disease*. (2021).

3. Kendall, E. A., Shrestha, S. & Dowdy, D. W. The Epidemiological Importance of Subclinical Tuberculosis. A Critical Reappraisal. *Am. J. Respir. Crit. Care Med.* **203**, 168–174 (2021).

4. Yoon, C., Dowdy, D. W., Esmail, H., MacPherson, P. & Schumacher, S. G. Screening for tuberculosis: time to move beyond symptoms. *Lancet Respir. Med.* **7**, 202–204 (2019).

5. CDC. Clinical Symptoms of Tuberculosis. *Tuberculosis (TB)* https://www.cdc.gov/tb/hcp/clinical-signs-and-symptoms/index.html (2024).

6. Richards, A. S. *et al.* Quantifying progression and regression across the spectrum of pulmonary tuberculosis: a data synthesis study. *Lancet Glob. Health* **11**, e684–e692 (2023).

7. Viglianti, E. M., Iwashyna, T. J. & Winkelman, T. N. A. Mass Incarceration and Pulmonary Health: Guidance for Clinicians. *Ann. Am. Thorac. Soc.* **15**, 409–412 (2018).

8. Emery, J. C. *et al.* Estimating the contribution of subclinical tuberculosis disease to transmission: An individual patient data analysis from prevalence surveys. *eLife* **12**, e82469 (2023).

9. da Silva Peres Bezerra, W. *et al.* The role of tuberculosis symptoms in transmission

risk to cell contacts in prisons. *MedRxiv Prepr. Serv. Health Sci.*

2025.05.27.25328413 (2025) doi:10.1101/2025.05.27.25328413.

10. Martinez, L. *et al.* Global, regional, and national estimates of tuberculosis incidence

and case detection among incarcerated individuals from 2000 to 2019: a systematic

analysis. *Lancet Public Health* **8**, e511–e519 (2023).

11. Walter, K. S. *et al.* The escalating tuberculosis crisis in central and South American

prisons. *Lancet Lond. Engl.* **397**, 1591–1596 (2021).

12. Cords, O. *et al.* Incidence and prevalence of tuberculosis in incarcerated

populations: a systematic review and meta-analysis. *Lancet Public Health* **6**, e300–

e308 (2021).

13. Zou, G. A Modified Poisson Regression Approach to Prospective Studies with

Binary Data. *Am. J. Epidemiol.* **159**, 702–706 (2004).

14. Sossen, B. *et al.* The natural history of untreated pulmonary tuberculosis in adults: a

systematic review and meta-analysis. *Lancet Respir. Med.* **11**, 367–379 (2023).

15. Bailey, S. L. *et al.* Missed opportunities for tuberculosis diagnosis. *Int. J. Tuberc.*

Lung Dis. Off. J. Int. Union Tuberc. Lung Dis. **15**, 205–i (2011).

 APPENDIX

 Supplementary Figure 1. Symptom persistence by baseline symptom status

 Risk tables with raw numbers of participants at each visit are shown beneath the curves.

 Alt text: Kaplan-Meier curves showing symptom persistence by baseline symptom status. Participants starting asymptomatic had a gradual decline in
 remaining asymptomatic, while those starting symptomatic showed rapid symptom resolution over follow-up visits.

 Supplementary Figure 2. Specific symptom changes by symptom transition group

 % of total instances of symptom transition in that symptom category. Symptom changes refer to new onset (Asymptomatic to Symptomatic group), resolution
 (Symptomatic to Asymptomatic), or either (Symptomatic to Symptomatic).
 Alt text: Heatmap showing percentage changes in specific symptoms by symptom transition group. Color intensity reflects percent change, highest
 among transitions involving cough-related symptoms.

Supplementary Table 1. Predictors of symptom change stratified by prior symptom status

Previously asymptomatic

Predictors	Becoming symptomatic		
	aRR*	95% CI	p-value
Previous TB	1.26	(1.08-1.47)	0.004
Current smoking	1.81	(1.53-2.15)	<0.001
Past smoking	1.34	(1.09-1.66)	0.005
Any drug use	1.23	(1.08-1.41)	0.002
Symptomatic cellmates	1.30	(1.15-1.47)	<0.001
TB contact	1.03	(0.91-1.17)	0.662
LunitTB ≥50	0.90	(0.78-1.04)	0.164

Previously symptomatic

Predictors	Becoming asymptomatic		
	aRR*	95% CI	p-value
Previous TB	0.94	(0.83-1.06)	0.340
Current smoking	0.82	(0.72-0.92)	0.001
Past smoking	0.96	(0.83-1.10)	0.563
Any drug use	0.88	(0.79-0.97)	0.010
Symptomatic cellmates	0.92	(0.84-1.00)	0.057
TB contact	0.92	(0.84-1.01)	0.077
LunitTB ≥50	0.98	(0.88-1.10)	0.784

349 *Adjusted risk ratios (aRRs) represent risk of symptom status change from prior status compared to no change in symptom status. Multivariate logistic regression
350 models with cluster-robust standard errors at the individual level to estimate odds of symptom transitions, adjusting for baseline characteristics including age,
351 prison, prior TB, smoking, drug use, prison time, symptomatic cellmates, TB contact, and categorical LunitTB x-ray score.